Form 4: Indivior Director Receives RSU Grant

Indivior Pharmaceuticals Director David E. Wheadon was granted 5,955 Restricted Stock Units, increasing his beneficial ownership to 20,350 shares.

Summary

• David E. Wheadon, a Director of Indivior Pharmaceuticals, Inc. (INDV), was granted 5,955 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant.
• Vesting is subject to Mr. Wheadon's continued service to the Issuer on the vesting date.
• Following this transaction, Mr. Wheadon beneficially owns 20,350 shares of Indivior Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive event as it increases insider ownership and aligns management's interests with shareholders, promoting long-term value creation.

Positives

• The grant of Restricted Stock Units to a director increases their direct stake in the company, aligning their interests more closely with those of shareholders.
• The vesting schedule encourages long-term commitment and continued service from the director.

Future Outlook

The granted Restricted Stock Units are set to vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the grant date, contingent upon the director's continued service.

Industry Context

Equity grants, such as Restricted Stock Units, are a standard component of executive and director compensation packages across various industries, designed to incentivize performance and align leadership interests with shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a compensation mechanism for directors is a common practice in publicly traded companies, aligning with typical corporate governance and incentive structures seen in the pharmaceutical industry and broader market.
• The vesting condition tied to continued service and the annual meeting date is a standard approach to ensure retention and long-term commitment, comparable to practices at peer companies like Johnson & Johnson or Pfizer, which also utilize equity-based compensation for their non-employee directors.

Related Party Transactions

• The grant of 5,955 Restricted Stock Units to David E. Wheadon, a Director of Indivior Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Increased alignment of a director's financial interests with shareholder value due to direct equity ownership.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The Restricted Stock Units will vest on the day immediately preceding the date of the first annual meeting of Indivior's stockholders following the grant date, subject to continued service.

Key Dates

Keywords

Indivior Pharmaceuticals, INDV, Restricted Stock Units, RSU grant, insider transaction, director compensation, equity award, beneficial ownership